<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Use of <z:chebi fb="0" ids="35664">statins</z:chebi> is hypothesized to reduce <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk but the evidence remains inconsistent </plain></SENT>
<SENT sid="1" pm="."><plain>This may be partly explained by differential associations according to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> location or molecular subtypes of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We examined the association between <z:chebi fb="0" ids="35664">statin</z:chebi> use and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk according to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> location, KRAS mutation status, microsatellite instability (MSI) status, PTGS2 (COX-2) expression, or CpG island methylator phenotype (CIMP) status in two large prospective cohort studies, the Nurses' Health Study and Health Professionals Follow-up Study </plain></SENT>
<SENT sid="3" pm="."><plain>We applied Cox regression to a competing risks analysis </plain></SENT>
<SENT sid="4" pm="."><plain>We identified 1,818 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> during 1990 to 2006 </plain></SENT>
<SENT sid="5" pm="."><plain>Compared with nonusers, current <z:chebi fb="0" ids="35664">statin</z:chebi> use was not associated with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> [relative risk (RR) = 0.99, 95% CI = 0.86-1.14] or <z:hpo ids='HP_0003003'>colon cancer</z:hpo> (RR = 1.10, 95% CI = 0.94-1.29) but was inversely associated with <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> (RR = 0.59, 95% CI = 0.41-0.84, P(<z:hpo ids='HP_0001425'>heterogeneity</z:hpo>) &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>When we examined the association within strata of KRAS mutation status, we found no association with KRAS-mutated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (RR = 1.20, 95% CI = 0.87-1.67) but did observe a possible inverse association among KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (RR = 0.80, 95% CI = 0.60-1.06, P(<z:hpo ids='HP_0001425'>heterogeneity</z:hpo>) = 0.06) </plain></SENT>
<SENT sid="7" pm="."><plain>The association did not substantially differ by PTGS2 expression, MSI status, or CIMP status </plain></SENT>
<SENT sid="8" pm="."><plain>Current <z:chebi fb="0" ids="35664">statin</z:chebi> use was not associated with risk of overall <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The possibility that <z:chebi fb="0" ids="35664">statin</z:chebi> use may be associated with lower risk of <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> or KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> requires further confirmation </plain></SENT>
</text></document>